# US 2026/0226467 A1 · Antisense oligomers for treatment of conditions and diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226467 A1
- Document ID: US20260226467A1
- Status: Published application
- Kind: A1
- Application number: 19/552,066
- Filed: 2026-02-27
- Published: 2026-08-06
- Earliest claimed: 2017-08-25
- Assignees: Stoke Therapeutics, Inc.
- Applicants: Stoke Therapeutics, Inc.
- Inventors: Isabel Aznarez; Zhou Han
- Web page: https://patentgrep.com/patent/US20260226467A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/12: for grand-mal
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/11: Antisense
- C12N 2310/321: 2'-O-R Modification
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/33: Alteration of splicing
- C12N 2320/35: based on a specific dosage / administration regimen
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Alternative splicing events in SCN1A gene can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in SCN1A gene can modulate the expression level of functional proteins in Dravet Syndrome patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition caused by SCN1A, SCN8A or SCN5A protein deficiency.

## Claims

### Claim 1

(canceled)

### Claim 2

A modified antisense oligomer, wherein the modified antisense oligomer comprises at least one modified nucleotide; wherein the modified nucleotide comprises a modification of a sugar moiety selected from the group consisting of a 2′-O(CH2)nNH2 modification, a 2′-O(CH2)nCH3, a 2′-O(CH2)nONH2 modification, a 2′-OCH2C(═O)N(H)CH3 modification, a 2′-O(CH2)nON[(CH2)nCH3]2 modification, and any combination thereof, wherein n is an integer from 1 to 10; and wherein the modified antisense oligomer comprises a sequence that is complementary to a target sequence of a pre-mRNA in a cell that contains a nonsense-mediated RNA decay inducing exon (NMD exon) and that encodes Nav1.1 protein, whereby hybridization of the modified antisense oligomer to the target sequence modulates splicing of the NMD exon from the pre-mRNA in the cell that contains the NMD exon and that encodes Nav1.1 protein.

### Claim 3 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer increases a level of processed mRNA encoding the Nav1.1 protein in the cell having the pre-mRNA that contains the NMD exon and that encodes Nav1.1 protein when the modified antisense oligomer is introduced into the cell.

### Claim 4 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer increases a level of the Nav1.1 protein in the cell having the pre-mRNA that contains the NMD exon and that encodes Nav1.1 protein when the modified antisense oligomer is introduced into the cell.

### Claim 5 (depends on 2)

The modified antisense oligomer of claim 2, wherein the target sequence:
(a) is within an intron sequence flanking the NMD exon;
(b) comprises at least one nucleotide of the NMD exon; or
(c) is within the NMD exon.

### Claim 6 (depends on 2)

The modified antisense oligomer of claim 2, wherein the pre-mRNA that contains the NMD exon and that encodes Nav1.1 protein comprises a sequence with at least about 95% sequence identity to any one of SEQ ID NOs: 2 or 7-10.

### Claim 7 (depends on 2)

The modified antisense oligomer of claim 2, wherein the target sequence of the pre-mRNA that contains the NMD exon and that encodes Nav1.1 protein comprises a sequence with at least about 95% sequence identity to a region comprising at least 8 contiguous nucleobases of SEQ ID NO: 2 or 7-10.

### Claim 8 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer further comprises an additional modification of a sugar moiety selected from the group consisting of a morpholine ring modification, a 2′-O-methyl modification, a 2′-O-aminoethyl modification, a 2′-fluoro modification, a 2′-O-methoxyethyl modification, and a 2′-O[(CH2)nO]mCH3 modification, wherein m is an integer from 1 to 10 and wherein n is an integer from 1 to 10.

### Claim 9 (depends on 8)

The modified antisense oligomer of claim 8, wherein the modified antisense oligomer comprises a 2′-O-methoxyethyl moiety.

### Claim 10 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer is from 8 to 50 nucleobases in length.

### Claim 11 (depends on 2)

The modified antisense oligomer of claim 2, wherein each modified nucleotide of the antisense oligomer comprises one or more identical modifications.

### Claim 12 (depends on 2)

The modified antisense oligomer of claim 2, wherein at least two of the modified nucleotides of the antisense oligomer comprise different modifications.

### Claim 13 (depends on 2)

The modified antisense oligomer of claim 2 wherein the modified antisense oligomer comprises a sequence that has at least about 80% sequence identity to any one of SEQ ID NOs: 21-61, 64-67, 210-250, 253-256, or 304-379.

### Claim 14 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer comprises a sequence that has at least about 90% sequence identity to any one of SEQ ID NOs: 21-61, 64-67, 210-250, 253-256, or 304-379.

### Claim 15 (depends on 14)

The modified antisense oligomer of claim 14, wherein the modified antisense oligomer comprises a sequence according to any one of SEQ ID NOs: 21-61, 64-67, 210-250, 253-256, or 304-379.

### Claim 16 (depends on 15)

The modified antisense oligomer of claim 15, wherein the sequence of the modified antisense oligomer consists of a sequence according to any one of SEQ ID NOs: 21-61, 64-67, 210-250, 253-256, or 304-379.

### Claim 17 (depends on 2)

The modified antisense oligomer of claim 2, wherein the antisense oligomer comprises a 2′-OCH2C(═O)N(H)CH3 modification of a sugar moiety.

### Claim 18 (depends on 17)

The modified antisense oligomer of claim 17, wherein the substituent group at the 2′-position of each sugar moiety of the modified antisense oligomer is 2′-OCH2C(═O)N(H)CH3.

### Claim 19 (depends on 2)

The modified antisense oligomer of claim 2, wherein the antisense oligomer comprises a 2′-OCH2C(═O)N(H)CH3 modification of a sugar moiety, and wherein the modified antisense oligomer comprises a sequence according to SEQ ID NO: 42 or 231.

### Claim 20 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer further comprises a modification of a nucleobase, wherein the modification of the nucleobase is selected from the group consisting of hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, 5-hydroxymethylcytosine, and any combination thereof.

### Claim 21 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer further comprises a modification of a backbone linkage, wherein the modification of the backbone linkage is selected from the group consisting of a phosphorothioate linkage, a phosphorodithioate linkage, a phosphoroselenoate linkage, a phosphorodiselenoate linkage, a phosphoroanilothioate linkage, a phosphoraniladate linkage, a phosphoramidate linkage, and any combination thereof.

### Claim 22 (depends on 21)

The modified antisense oligomer of claim 21, wherein the modification of the backbone linkage is a phosphorothioate linkage.

### Claim 23 (depends on 21)

The modified antisense oligomer of claim 21, wherein the modification of the backbone linkage is a phosphoramidate linkage.

### Claim 24 (depends on 21)

The modified antisense oligomer of claim 21, wherein the modified antisense oligomer comprises at least one phosphodiester linkage and at least one phosphorothioate linkage.

### Claim 25 (depends on 2)

The modified antisense oligomer of claim 2, wherein the modified antisense oligomer further comprises: (i) a modified nucleobase comprising a 5-methylcytosine, (ii) at least one phosphodiester linkage and (iii) at least one phosphorothioate linkage.

### Claim 26 (depends on 25)

The modified antisense oligomer of claim 25, wherein the modified antisense oligomer comprises a modification of a sugar moiety having a substituent group at the 2′-position that is 2′-OCH2C(═O)N(H)CH3.

### Claim 27 (depends on 26)

The modified antisense oligomer of claim 26, wherein the substituent group at the 2′-position of each sugar moiety of the modified antisense oligomer is 2′-OCH2C(═O)N(H)CH3.

### Claim 28 (depends on 26)

The modified antisense oligomer of claim 26, wherein the substituent group at the 2′-position of each sugar moiety of the modified antisense oligomer is 2′-OCH2C(═O)N(H)CH3 or 2′-O-methoxyethyl.

### Claim 29 (depends on 2)

The modified antisense oligomer of claim 2, wherein the antisense oligomer comprises a 2′-OCH2C(═O)N(H)CH3 modification of a sugar moiety, wherein the modified antisense oligomer further comprises at least one phosphodiester linkage and at least one phosphorothioate linkage, and wherein the modified antisense oligomer comprises a sequence according to SEQ ID NO: 42 or 231.

### Claim 30 (depends on 2)

A pharmaceutical composition comprising the modified antisense oligomer of claim 2 and a pharmaceutically acceptable excipient.

### Claim 31 (depends on 29)

A method of treating a disease or condition in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 29 to the subject.
